Warning letter
Allure Labs, Inc. [ARCHIVED]: warning letter of May 24, 2011
FDA warning letter 155413 · San Francisco District Office
Key facts
| Reference number | 155413 |
|---|---|
| Company | Allure Labs, Inc. [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Misbranded/Adulterated |
| Issue date | May 24, 2011 |
| Posted date | May 24, 2011 |
| Issuing office | San Francisco District Office |
| Product type | Drugs |
| CFR sections cited | 201.5, 201.66, 310.502, 310.530, 211.22(a), 211.25(a), 211.100(a), 211.113(a), 211.160(b), 310.3(h)(5), 310.502(a)(14) |
| Inspection city | Hayward |
| Inspection ZIP | 94544 |
| Inspection start date | Oct 18, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: